Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of
Estracyt
, a Nitrogen mustard (HN2) derivative of estradiol-17 beta versus the free HN2 on cell kinetics of the estrogen receptor positive human
endometrial cancer
cell line HEC-1 were investigated using flow cytometry. The results were as follows. The cell killing effects of
Estracyt
existed in a dependency on dose and time, whereas those of HN2 were dependent on dose alone. HN2 at 1 microgram/ml showed a marked increase in S phase and decrease in G0+1 phase. However, with equivalent doses of
Estracyt
at 10 micrograms/ml, even more remarkable was the accumulation in the G2+M phase. Synchronization at S phase with MTX showed no increase in sensitivity to these drugs on cells in S phase. Based on the above results, it was suggested that the free HN2 had an affect regardless of the cell cycle phase, whereas the effects of
Estracyt
corresponded to the cell cycle phase and
Estracyt
might have a fixed population of non-target cells existing in the G0+1 and S phase. Synchronization in the G1 phase with Sodium n-butylate could increase the target effects of
Estracyt
in S phase.
...
PMID:[The effects of site-directed chemotherapy due to E2 as a drug carrier to the human endometrial adenocarcinoma cells in vitro]. 398 43
